Longeveron Inc., a clinical-stage biotech company specializing in cellular therapies for rare pediatric and aging-related conditions, will release its Q1 2026 financial results on May 13 after market close. The company will also provide a business update and hold a conference call and webcast at 4:30 p.m. ET the same day. Longeveron's lead product, laromestrocel, targets multiple serious diseases and has received several FDA designations, highlighting its potential. Investors can expect updates on ongoing trials and company progress during the call.
The global GLP-1 receptor agonist market, used primarily for type 2 diabetes and obesity management, is projected to grow from $28.7 billion in 2025 to $95.3 billion by 2035, at a compound annual growth rate of 12.1%. Growth is fueled by rising diabe...
17 Education & Technology Group Inc. reported a strong first quarter for 2026 with net revenues soaring 359% year-over-year to RMB99.5 million, driven by its AI-powered personalized learning app Yiqi Aixue. The company improved its gross margin to 61...
The Schall Law Firm is investigating Simulations Plus, Inc. for potentially issuing false or misleading statements and failing to disclose important information to investors. This probe could impact shareholders who may have suffered losses due to th...
Brodsky & Smith LLC has announced investigations into the merger agreements of Simulations Plus, Roku, TruBridge, and Organon. The investigations focus on whether the respective company boards breached their fiduciary duties by not ensuring a fair pr...
Jeppesen ForeFlight has received the Department of Defense Impact Level 5 (IL5) Authority to Operate, the highest cybersecurity clearance for unclassified cloud systems. This authorization allows military and defense organizations to use ForeFlight f...
